• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Hologic to buy Cynosure in $1.65B deal

Hologic to buy Cynosure in $1.65B deal

February 14, 2017 By Sarah Faulkner

Hologic to buy Cynosure in $1.65B dealHologic (NSDQ:HOLX) said today that it landed a deal to acquire Cynosure Inc. (NSDQ:CYNO) and its portfolio of medical aesthetics products for $1.65 billion.

Marlborough, Mass.-based Hologic offered $66 per share – a 28% premium compared to Cynosure’s close yesterday.

The transaction, which has a reported enterprise value of $1.44 billion, comes 1 day after Allergan announced its plans to buy Cynosure’s rival Zeltiq Aesthetics for $2.48 billion.

Cynosure develops products for non-invasive body contouring, hair removal, women’s health and skin revitalization.

“Acquiring Cynosure will accelerate our transformation into a higher-growth company by leveraging our core women’s health expertise and OB/GYN channel leadership into an adjacent, cash-pay segment that is expanding at a low double-digit rate,” Hologic chairman, president & CEO Steve MacMillan said in prepared remarks. “We had identified medical aesthetics as an attractive and complementary growth opportunity through our strategic planning process, and are pleased to have agreed to acquire Cynosure, the best-in-class company in the space.  Together, we can strengthen our shared focus on innovation, market-leading products with demonstrated clinical benefits, and strong customer relationships.”

Morgan Stanley & Co. acted as Hologic’s financial adviser and Watchtell, Lipton, Rosen & Katz served as the company’s legal adviser. Leerink Partners was financial adviser to Cynosure, while Wilmer Cutler Pickering Hale and Dorr served as its legal adviser.

“We are thrilled at the prospect of becoming part of Hologic through a transaction that provides excellent value for all of our stakeholders,” Cynosure’s chairman, president & CEO Michael Davin added. “Strategically, this deal enables Cynosure to further capitalize on growth opportunities in the core and non-core aesthetic market, rapidly strengthens our position in women’s health – where Hologic has a leading commercial presence – and accelerates our R&D initiatives.”

CYNO shares soared 27.9% this morning to $65.85 apiece, while HOLX shares were trading at $38.83 per share, down -3.3%.

Shares in Hologic fell earlier this month even though the company beat expectations on Wall Street with its 1st quarter results.

The company posted profits of $86.5 million, or 30¢ per share, on sales of $734 million for the 3 months ended December 31, for bottom-line growth of 1.9% while sales grew 5.6% compared with the same period in the previous year.

Adjusted to exclude 1-time items net profits were $148.1 million and earnings per share were 52¢, ahead of consensus on The Street where analysts were looking for revenue of $724 million.

Material from Reuters was used in this report.

Filed Under: Cosmetic/Aesthetic, Mergers & Acquisitions, Wall Street Beat, Women's Health Tagged With: Cynosure Inc., Hologic

More recent news

  • Terumo Neuro launches new stroke catheter in the U.S.
  • EnVVeno has first-in-human heart valve data, expects FDA decision this year
  • Axoft makes Fleuron BCI material available for purchase, inks license deal with Stanford
  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy